Recent clinical studies have demonstrated that combining pembrolizumab (Keytruda) with olaparib (Lynparza) significantly improves progression-free survival (PFS) in patients with advanced epithelial ovarian cancer lacking BRCA mutations. In the phase 3 KEYLYNK-001 trial, patients receiving pembrolizumab plus chemotherapy followed by maintenance therapy with pembrolizumab and olaparib, with or without bevacizumab (Avastin), experienced a statistically significant and clinically meaningful improvement in PFS compared to those receiving chemotherapy alone.
Specifically, the median PFS in the pembrolizumab-olaparib group was 22.2 months, compared to 14.6 months in the control group. Notably, among patients with a PD-L1 combined positive score (CPS) of 10 or higher, the median PFS was 16.4 months for the pembrolizumab-olaparib group versus 10.2 months for the control group. However, this combination therapy did not show a significant improvement in overall survival (OS) across the entire study population. Click for More Details
